Vaccine Therapy for Patients With Stage III Melanoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00052130|
Recruitment Status : Unknown
Verified September 2004 by CancerVax Corporation.
Recruitment status was: Active, not recruiting
First Posted : January 24, 2003
Last Update Posted : June 24, 2005
|Condition or disease||Intervention/treatment||Phase|
|Malignant Melanoma||Biological: CancerVax vaccine (CANVAXIN)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||1118 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00052130